<DOC>
	<DOCNO>NCT02629159</DOCNO>
	<brief_summary>This phase 3 , randomize , double-blind study compare ABT-494 Placebo Adalimumab subject moderately severely active rheumatoid arthritis stable background Methotrexate ( MTX ) inadequate response MTX .</brief_summary>
	<brief_title>A Study Comparing ABT-494 Placebo Adalimumab Subjects With Rheumatoid Arthritis Who Are Stable Dose Methotrexate Who Have Inadequate Response Methotrexate</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Adult male female , least 18 year old . Diagnosis RA great equal 3 month . Subjects must oral parenteral methotrexate ( MTX ) therapy great equal 3 month stable prescription great equal 15 25 mg/week ( great equal 10 mg/week subject intolerant MTX dose great equal 15 mg/week ) great equal 4 week prior first dose study drug . In addition subject take dietary supplement folic acid folinic acid throughout study participation . Meets follow minimum disease activity criterion : great equal 6 swollen joint ( base 66 joint count ) great equal 6 tender joint ( base 68 joint count ) Screening Baseline Visits . At least one follow Screening : great equal 3 bone erosion xray OR great equal 1 bone erosion positive rheumatoid factor OR great equal 1 bone erosion positive anticyclic citrullinated peptide autoantibody . Subjects prior exposure one Biological diseasemodifying antirheumatic drug ( bDMARD ) ( except ADA ) may enrol ( 20 % total study population ) document evidence intolerance bDMARD limit exposure ( le 3 month ) , require washout period need satisfy . Except MTX , subject must discontinue conventional synthetic diseasemodifying antirheumatic drug ( csDMARDs ) . Prior exposure Janus kinase ( JAK ) inhibitor ( include limit tofacitinib , baricitinib , filgotinib ) . Subjects expose adalimumab consider inadequate responder bDMARD therapy determine Investigator . History inflammatory joint disease RA . History secondary Sjogren 's Syndrome permit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Antirheumatic agent</keyword>
	<keyword>Anti-inflammatory agent</keyword>
	<keyword>Musculoskeletal disease</keyword>
	<keyword>Arthritis</keyword>
	<keyword>Joint disease</keyword>
</DOC>